1,969 Shares of IDEXX Laboratories, Inc. $IDXX Bought by Robinson Smith Wealth Advisors LLC

Robinson Smith Wealth Advisors LLC bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,969 shares of the company’s stock, valued at approximately $1,028,000.

Several other hedge funds also recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $628,223,000. Arrowstreet Capital Limited Partnership grew its stake in IDEXX Laboratories by 52.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after acquiring an additional 288,471 shares during the period. Alyeska Investment Group L.P. grew its stake in IDEXX Laboratories by 97.3% in the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock worth $211,146,000 after acquiring an additional 197,808 shares during the period. Montrusco Bolton Investments Inc. raised its holdings in IDEXX Laboratories by 93.4% in the 1st quarter. Montrusco Bolton Investments Inc. now owns 342,120 shares of the company’s stock valued at $186,707,000 after acquiring an additional 165,188 shares during the last quarter. Finally, American Capital Management Inc. acquired a new position in IDEXX Laboratories in the 2nd quarter valued at $85,341,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IDXX has been the topic of several recent analyst reports. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Citigroup boosted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. UBS Group boosted their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Barclays cut their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Finally, JPMorgan Chase & Co. cut their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research note on Friday, October 16th. Seven equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $744.09.

Insider Buying and Selling

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $566.76 on Friday. The company’s fifty day simple moving average is $532.51 and its 200-day simple moving average is $551.58. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company has a market cap of $44.65 billion, a PE ratio of 39.86, a P/E/G ratio of 2.96 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same period in the prior year, the firm earned $3.50 EPS. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.